Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Apollo Healthcare Corp Warrants (03/01/2022) APHWF

Based in Ontario Canada the Apollo Healthcare Corp Apollo is one of the largest private label personal care product manufacturers in North America developing and manufacturing retailer branded and private label products for major North American retailers. Apollos products are sold in tens of thousands of stores across North America and its customer base spans across major North American grocery drug and mass merchandise retailers users as well as wholesale clubs. In addition to private label Apollo also manufactures products on a contract basis for many of its clients.


OTCPK:APHWF - Post by User

Comment by RTOon Mar 05, 2021 7:18am
151 Views
Post# 32725824

RE:RE:Projected EPS $1.05

RE:RE:Projected EPS $1.05GARY, the previous Ascasta financials cannot be a measure nor relied upon because the company was still working through the process of unwinding the two other unrelated entities that were being sold off from the previous SPAC (Acasta) holding structure.  That is where those operating losses came from and have been applied to AHC at this very moment last year, when COVID started.  Apollo was purchased for $390 million or around $6.00/share.  You would need to look at THOSE financials several years back to get a baseline and to see where COVID, operating tax loss crystallization (+ $90 million), market growth expansion & the CBD wildcard takes it from here.  Only those shareholders that have been here long enough (very few if any, other than board insiders), or have performed DD above and beyond the regular call of duty will unerstand what is going on here. 
<< Previous
Bullboard Posts
Next >>